Reata Pharma (RETA) Tops Q1 EPS by 94c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Reata Pharma (RETA) Tops Q1 EPS by 94c

Reata Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs

May 6, 2021 6:45 AM EDT

ANNOUNCES FDA ACCEPTED FOR FILING REATAS NDA OF BARDOXOLONE FOR THE TREATMENT OF PATIENTS WITH CKD CAUSED BY ALPORT SYNDROME

IF APPROVED, BARDOXOLONE MAY BECOME THE FIRST APPROVED THERAPY FOR ALPORT SYNDROME, A LIFE-THREATENING DISEASE THAT AFFECTS 30,000 60,000 PATIENTS IN THE U.S.

REAFFIRMS ANTICIPATED COMPLETION OF ENROLLMENT BY END OF 2021 IN PHASE 3 FALCON TRIAL FOR ADPKD

FDA GRANTED TYPE C MEETING TO DISCUSS FA DEVELOPMENT PROGRAM IN 2Q 2021

CONFIRMS CASH RUNWAY THROUGH... More